Suzhou Basecare Medical Corporation Limited (HKG:2170)

Market Cap	380.20M -54.0%
Revenue (ttm)	259.59M -22.0%
Net Income	-248.66M
EPS	-0.91
Shares Out	273.53M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,500
Open	1.350
Previous Close	1.410
Day's Range	1.350 - 1.390
52-Week Range	1.230 - 4.360
Beta	0.01
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About HKG:2170

Suzhou Basecare Medical Corporation Limited, an investment holding company provides genetic testing solutions for assisted human reproduction in the People’s Republic of China and Australia. The company offers pre-implantation genetic test kits, including PGT-A kit to detect aneuploidy; PGT-M kit to detect single-gene or monogenic defects in pre-implantation embryos; and PGT-SR kit to detect chromosome structural rearrangements, which are common causes of recurrent miscarriage, implantation failures, and birth defects. It also provides DA500, a...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2010
• Employees: 407
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2170

Financial Performance

In 2025, HKG:2170's revenue was 233.27 million, a decrease of -22.01% compared to the previous year's 299.11 million. Losses were -223.46 million, -5.73% less than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 10, 2026

Data Sources Report a data error